Report
Shelley Moen
EUR 231.76 For Business Accounts Only

Vermilion Compass: Weekly Equity Strategy

Market Observations:

• We remain bullish on the equities markets. The 10-year Treasury
yield remains in a defined trading range, which we think will persist.

• Much is happening within individual Sectors, however. Last week
we downgraded the Energy Sector to an underweight and reduced
to underweight the “defensive” Consumer Staples and Utilities
Sectors. This was prudent as Energy has become a source of
funds, after crude oil's trend has lost momentum and direction so
far in 2017, while the market rotates toward a higher-beta mentality,
driving most indices to new highs.

• The Consumer Discretionary Sector is starting to show signs of
life, but it's early. Restaurants have vaulted to a shared leadership
position alongside the homebuilders and related stocks. See
Insights report emailed last week entitled, “Hungry Restaurants.”
The retailers, long the drag on the Sector, are showing signs of
stabilization as well.

• The Communications and Health Care Sectors are the latest upand-
comers. Media and Internet-related companies/Groups are the
standouts in Communications. If the Telecomm Services area was
acting better, we'd feel compelled to upgrade the recommended
weighting. Health Care is showing much-improved breadth, as
leadership from devices is being complemented by continued improving
breadth in biotech.

• Technology continues to be the dominant market leadership; from
semis, to data storage, to software, the breadth is tremendous.

For a trial to Vermilion Research visit our website at www.vermilioncap.com or contact our sales team at (952) 922-7500.
Underlying
ABIOMED Inc.

ABIOMED is a provider of temporary mechanical circulatory support devices, and it provides a continuum of care to heart failure patients. The company's products include: Impella 2.5?, which is a percutaneous micro heart pump with an integrated motor and sensors; which is primarily used by either interventional cardiologists to support patients in the cath lab or by cardiac surgeons in the heart surgery suite; Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, which is a percutaneous catheter-based axial flow pump that is designed to allow more than four liters of flow per minute.

Provider
Vermilion Research
Vermilion Research

Vermilion Research delivers timely, actionable, and unique research inputs to professional investors. Our research strategists highlight securities which we believe are at major inflection points, based on our various proprietary technical indicators, and offer asymmetric risk/return profiles. We believe our research methodology, which is not limited by industry sector or market capitalization, enables us to deliver superior investment recommendations.

Our process begins by organizing all actively traded stocks into coherent sectors, then into logical industry groups. We then apply our proprietary relative strength tools to identify developing price trends. Once attractive trends are identified within a selected sectors or groups, we screen for individual stocks which we believe offer the best risk/reward profile. Vermilion offers U.S. and global equity market research products. Vermilion’s research team, which has received numerous awards and accolades, has a combined 70 year of experience in the analysis of investment securities.

Analysts
Shelley Moen

Other Reports on these Companies
Other Reports from Vermilion Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch